Health

STAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 05/10/2026, 12:21:24 UTC.

Briefings

Vaxcyte announced its experimental pneumococcal vaccine VAX-31 successfully met primary endpoints in a Phase 3 trial, positioning it to compete with Pfizer's Prevnar and Merck's Capvaxive. The trial enrolled over 3,500 adults aged 50 and older, who were randomized to receive one of the three vaccines. Investigators assessed antibody response strength against various bacterial strains. The study concluded that VAX-31 achieved the primary goals, though the specific efficacy percentages and long-term safety data remain to be fully detailed in the full report.

Key points

• Vaxcyte's experimental pneumococcal vaccine VAX-31 met primary endpoints in a Phase 3 clinical trial, enabling competition with Pfizer's Prevnar and Merck's Capvaxive.
• The trial included over 3,500 adults aged 50 and older, who were randomized to receive VAX-31, Prevnar, or Capvaxive to measure antibody response strength against various bacterial strains.

Context and limitations

The provided evidence covers the successful completion of primary endpoints in a Phase 3 trial for VAX-31, but specific efficacy percentages, long-term safety data, and detailed strain comparisons are not included in the source text.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 05/10/2026, 21:06:39 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeigpqfbs4nhd4udszluuekb5eai3k6twcnyhnn3xcxoj2a3xfbug5y